Phase II
The company indicates that the overall data from the vixotrigine program will help them determine dose levels for future Phase III trials.
Brukinsa was approved for MSL patients who have received at least one anti-CD20-based regimen.
NovoCure and Roche aim to explore the combined efficacy of TTFields with atezolizumab as a potential treatment for pancreatic cancer.
The Phase II study showed enhanced immune memory response to the virus in 96% of vaccinated subjects, all of whom were exposed to an environment dominated by the delta variant.
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.
Novartis announced that it is discontinuing the trial in kidney transplant patients after conducting an interim analysis from its CIRRUS-1 trial of CFZ533 (iscalimab).
There were a fair number of clinical trial announcements last week. Here’s a look.
Shares of Forte Biosciences plunged more than 80% in premarket trading after the company announced failure to demonstrate statistical significance of Phase II atopic dermatitis trial.
PRESS RELEASES